Showing 672 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

Pharmaceutical industry

Under new leadership, CytoDyn ditches COVID-19 programs

Editor's pick
FierceBiotech
30 September 2022
New & experimental HIV treatments

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
20 September 2022
Injectable & long-acting HIV treatment

Long-Acting Injectable HIV Therapy for People Who Won’t Take ART?

Editor's pick
NEJM Journal Watch
10 August 2022
New & experimental HIV treatments

Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir

Editor's pick
Gilead Sciences press release
28 July 2022
New & experimental HIV treatments

Fostemsavir Plus Optimized Background Therapy May Be Viable for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
30 June 2022
New & experimental HIV treatments

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

Editor's pick
Gilead Sciences press release
28 June 2022
Injectable & long-acting HIV treatment

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Editor's pick
Gilead Sciences press release
25 June 2022
New & experimental HIV treatments

Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120

Editor's pick
GlobeNewswire (press release)
13 June 2022
New & experimental HIV treatments

FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV

Editor's pick
Gilead Sciences press release
18 May 2022
New & experimental HIV treatments

After FDA hold, CytoDyn will appeal for pharma partnerships to save leronlimab

Editor's pick
FierceBiotech
31 March 2022
New & experimental HIV treatments

U.S. FDA declines to approve Gilead's HIV drug on glass vial concerns

Editor's pick
Reuters
1 March 2022
New & experimental HIV treatments

Antiviral Efficacy, Safety, Tolerability of a Novel HIV-1 Maturation Inhibitor (GSK'254)

Editor's pick
Infectious Disease Advisor
31 January 2022
Pharmaceutical industry

CytoDyn board ousts CEO after a wild year, leaving an albatross of a C-suite job to fill

Editor's pick
FierceBiotech
27 January 2022
Pharmaceutical industry

Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multi-pronged R&D strategy

Editor's pick
FierceBiotech
7 December 2021
PrEP science

Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection

Editor's pick
BusinessWire
7 December 2021
New & experimental HIV treatments

Gilead and Merck Announce Temporary Pause in Enrolment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir ​​​​​​​

Editor's pick
Gilead Sciences
26 November 2021
New & experimental HIV treatments

Merck pauses 'very important' HIV program after seeing red flag in phase 2 trial of once-weekly combo

Editor's pick
FierceBiotech
22 November 2021
New & experimental HIV treatments

Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1

Editor's pick
Merck press release
19 November 2021
Injectable & long-acting HIV treatment

England & Wales: NICE approves first long-acting injectable HIV-1 treatment

Editor's pick
National Institute for Health and Care Excellence
18 November 2021
New & experimental HIV treatments

Merck's HIV program closer to regulator's doorstep with two phase 3 trials showing efficacy comparable to existing meds

Editor's pick
FierceBiotech
31 October 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

Editor's pick
ViiV Healthcare
28 October 2021
Injectable & long-acting HIV treatment

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

Editor's pick
Gilead press release
26 October 2021
New & experimental HIV treatments

Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
25 October 2021
Injectable & long-acting HIV treatment

Cabotegravir (Vocabria®) is accepted for use within NHSScotland

Editor's pick
Scottish Medicines Consortium
11 October 2021